Clinical Trial Update: Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BR2251 tablets in primary gout with hyperuricemia; the study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• BR2251 Tablets

Snippet

Sponsor: BioRay Pharmaceutical Co., Ltd. | Conditions: Gout and Hyperuricemia | Phase 2 | Status: NOT_YET_RECRUITING